【Objective】 To evaluate the impact of COVID-19 epidemic prevention and control on blood collection and supply, so as to accumulate experience for future similar public events. 【Methods】 The annual inventory before Spring Festival holiday, the supply of red blood cells and apheresis platelets during Spring Festival (from New year′s Eve to lunar January 6th) and the collection and supply units 3 months after the Spring Festival (the lunar January 7th to April 8th) during 2017 to 2020 were analyzed to evaluate the impact of the epidemic on blood collection, supply and inventory management. 【Results】 The inventory and its proportion in 2020 decreased to 14 594 U and 23.89%, compared with those in 2018 (16 095 U, 26.34%) and 2019 (16 301 U, 26.68%), with significant differences (P<0.05). The COVID-19 epidemic(3-month-post Spring Festival in 2019 and 2020) reduced the blood collection in urban areas(28 613 U and 19 901 U) and group donation (17 443 U and 5 332 U), but rasied blood collection in towns (43 184 U and 50 963 U). The clinical blood consumption in year 2017, 2018, 2019 and 2020 was 80 339 U, 79 359 U, 87 581 U and 74 986 U, respectively, decreasing due to the epidemic (P<0.05), with a small amount(229 U) of red blood cell discarding owing to expiration. The collection and supply of apheresis platelets were minimally affected by the epidemic. 【Conclusion】 The epidemic had a direct/indirect impact on blood collection, blood supply and inventory management, except for apheresis platelets collection and supply. It suggests that the characteristics of COVID-19 prevention and control measures can be used as references for future precise organization and targeted recruitment of blood resources in case of the similar emergencies. Close communication with clinical departments contributes to the safeguard of emergency transfusion and the prevention of blood expiration.

【Objective】 To investigate the effect of leukocyte-depleted suspended red blood cells (lds-RBCs) storaged for different time on blood transfusion effect of patients with hematologic diseases and malignant tumors, as well as to evaluate the storage quality of lds-RBCs in blood stations. 【Methods】 Seven hospitals (4 tertiary-A hospitals and 3 secondary-A hospitals), applying for blood from our blood center, were selected. Blood transfusion cases (medical record) and related data (indicators) of patients with blood diseases and malignant tumors in those hospitals from December 2018 to May 2019 were collected, including disease diagnosis (type) before transfusion, demographic characteristics, date of solo transfusion of lds-RBCs, units of lds-RBCs [(1~2)U/bag, 1 U=200 mL whole blood], different storage duration (1~5 weeks) (bar code), and hemoglobin (Hb) 48 h before and after transfusion. The efficacy of lds-RBCs (storaged for different time) transfusion in patients with hematologic diseases and malignant tumors was evaluated by statistical analysis. 【Results】 A total of 3 557 patients with hematologic diseases and malignant tumors were enrolled in this study. No significant changes were noticed in transfusion efficacy by blood transfusion unit, gender and previous transfusion history (P > 0.05). The effective rate of lds-RBCs in patients with blood diseases and malignant tumors, stratified by storage duration, i. e. storaged for >1~2 weeks, >2~3 weeks, >3~4 weeks and more than >4~5 weeks, was 78.77% vs 77.68% vs 75.06% vs 70.37%, and 79.32% vs 76.73% vs 72.79% vs 67.65%, respectively(P<0.05), with lds-RBCs of 4-5 storage weeks presenting the lowest transfusion efficacy in both groups of patients. 【Conclusion】 The storage time of most lds-RBCs supplied by our center is moren than 3 weeks, and the transfusion effect of lds-RBCs stored for 5 weeks needs further observation. In order to ensure and improve the efficacy of blood transfusion, evidence-based medicine and information management are needed to help the clinical gasp the advantageous time of blood products and shorten the storage-to-transfusion time of red blood cells.